From None: 2024-12-17 11:29:00

Exelixis (NASDAQ:EXEL) shares dropped 4% after BofA Securities downgraded the company to Neutral with a price target of $39. The stock had surged 37% due to positive news, but analysts are cautious about the company’s pipeline and lack of catalysts in 2025.

Investor focus on Exelixis’ next-generation TKI candidate, zanza, is high, but analysts believe that key data and trials are already factored into the stock price. The Phase 1/2 basket trial for zanza offers limited upside, and Cabo’s label expansion into NET is not expected to significantly impact the company’s NPV.



Read more at None:: Exelixis Downgraded as Risk-Reward Balance Shifts …